Loading stock data…
OCS
$29.58+1.83 (+6.59%)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Oculis Holding AG in the Healthcare sector is trading at $29.58. The stock is currently near its 52-week high of $30.68, remaining 32.8% above its 200-day moving average. Technical signals show neutral RSI of 61 and bullish MACD crossover, explaining why OCS maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 61) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$29.58
Potential Upside
5%
Whystock Fair Value$31.06
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$48.17+62.9%
Range$38.27 – $56.68
Fundamentals
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dex...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.61B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.88%
Volume
Today's trading volume
263,894
Recent News
TG Therapeutics (TGTX) Q1 Earnings Lag Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -26.88% and +2.81%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Should Oculis Completing Phase 3 Trials for Topical DME Drug OCS-01 Require Action From OCS Investors?
Oculis Holding AG recently completed the final patient visits in its two Phase 3 DIAMOND trials of OCS-01, a topical dexamethasone eye drop being studied over 52 weeks as a potential first non-invasive treatment for diabetic macular edema, with topline data now expected in June 2026 and a possible NDA filing later in the year. This milestone underscores how OCS-01, enabled by Oculis’ OPTIREACH formulation technology, could address a large group of DME patients who remain untreated or respond...
Oculis Holding (NasdaqGM:OCS) Valuation Check After Strong Three Year Gains And Recent Share Price Pullback
What Oculis Holding’s Recent Performance Tells You Oculis Holding (NasdaqGM:OCS) has drawn investor attention after a strong past 3 months return of about 31%, alongside a year to date gain of roughly 35% and a 1 year total return near 43%. See our latest analysis for Oculis Holding. In the short term, the 1 week share price return of about an 8% decline and the 1 month share price return of roughly a 5% decline contrast with a 3 month share price return near 31% and a 3 year total...
Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) delivered earnings and revenue surprises of -17.70% and +83.68%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Oculis Holding (NasdaqGM:OCS) Valuation Check As Privosegtor Wins FDA Breakthrough Therapy Status
Oculis Holding (OCS) is back in focus after the U.S. FDA granted breakthrough therapy designation to its neuroprotective candidate Privosegtor for optic neuritis, supported by positive Phase 2 ACUITY trial data. See our latest analysis for Oculis Holding. The breakthrough therapy designation appears to have coincided with stronger trading interest, with a 1 day share price return of 4.72% and 7 day share price return of 15.35% at a latest share price of $23.07. Over longer periods, the stock...